Yu. O. Shalaginova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu. O. Shalaginova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Roman M. Shakhnovich
Chazov National Medical Research Center of Cardiology
2 shared publications - Anna G. Komarova
Botkin Hospital
1 shared publication Dmitry Pevzner
Department of Acute Cardiology, E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russia
1 shared publication- I. I. Staroverov
Chazov National Medical Research Center of Cardiology
1 shared publication Igor Yavelov
Department of Fundamental and Clinical Problems of Thrombosis in Non-Communicable Diseases, National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
1 shared publicationKsenia Vitalieva
Department of Acute Cardiology, E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (22) , 108054
Apical Takotsubo Syndrome After Elective Stenting of the Left Anterior Descending Artery
- 1 May 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (22) , 108054
Open AccessApical Takotsubo Syndrome After Elective Stenting of the Left Anterior Descending Artery
- 10 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (9)
Ticagrelor monotherapy as a strategy to reduce the bleeding risk in patients with acute coronary syndrome who underwent percutaneous coronary intervention
It is known that the risk of thrombotic events in patients with acute coronary syndrome (ACS) is highest in the first year after the event. Regardless of the treatment tactics, dual antiplatelet therapy (DAPT) is prescribed for a year after. DAPT significantly prevents thrombotic events, primarily recurrent myocardial infarction. At the same time, the bleeding risk naturally increases. In recent years, convincing data have been obtained that the transition from DAPT to ticagrelor monotherapy 1-3 months after the event leads to a significant reduction in the bleeding risk without increasing the rate of thrombotic events compared to 12-month DAPT. The review analyzes data from randomized clinical trials comparing DAPT and ticagrelor monotherapy in patients with ACS and presents the provisions of Russian and international clinical guidelines for the treatment of ACS regarding ticagrelor monotherapy. The review aim is to rationale the advantage of ticagrelor monotherapy compared to standard DAPT in patients with ACS and percutaneous coronary intervention using a detailed analysis of randomized controlled trials and meta-analyses. The practical part presents the relevant sections of the clinical guidelines.
- 10 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (9)
Ticagrelor monotherapy as a strategy to reduce the bleeding risk in patients with acute coronary syndrome who underwent percutaneous coronary intervention
It is known that the risk of thrombotic events in patients with acute coronary syndrome (ACS) is highest in the first year after the event. Regardless of the treatment tactics, dual antiplatelet therapy (DAPT) is prescribed for a year after. DAPT significantly prevents thrombotic events, primarily recurrent myocardial infarction. At the same time, the bleeding risk naturally increases. In recent years, convincing data have been obtained that the transition from DAPT to ticagrelor monotherapy 1-3 months after the event leads to a significant reduction in the bleeding risk without increasing the rate of thrombotic events compared to 12-month DAPT. The review analyzes data from randomized clinical trials comparing DAPT and ticagrelor monotherapy in patients with ACS and presents the provisions of Russian and international clinical guidelines for the treatment of ACS regarding ticagrelor monotherapy. The review aim is to rationale the advantage of ticagrelor monotherapy compared to standard DAPT in patients with ACS and percutaneous coronary intervention using a detailed analysis of randomized controlled trials and meta-analyses. The practical part presents the relevant sections of the clinical guidelines.
- Open Access
- 3 August 2023
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 13 (1) , 58-72
Features of myocardial characteristics of patients with acute ST-segment elevation myocardial infarction with diabetes mellitus as assessed by contrast-enhanced cardiac magnetic resonance imaging
Introduction. The presence of diabetes mellitus in patients with acute infarction significantly worsens short- and long-term prognosis, but the features of the course of the infarction in this category of patients have not been fully studied.Objective. To compare clinical, functional and structural myocardial characteristics of patients with acute ST-segment elevation myocardial infarction with and without diabetes mellitus.Materials and methods. The study included 91 patients with revascularized ST-segment elevation myocardial infarction (41 patients with diabetes mellitus). All patients underwent cardiac MRI with contrast, including myocardial T1 mapping, tissue analysis of left ventricular myocardium with determination of infarct zone, heterogeneous zone, edema zone, pre- and post-contrast T1 values, extracellular volume values of healthy myocardium and infarct zone.Results. The presence of diabetes in patients with AMI was associated with increased EDV LV: 153 ± 38 and 181 ± 58 ml (p = 0.007), increased ESV LV: 76 ml [54–93] and 87 ml [71–122] (p = 0.035). Infarct size was significantly larger in patients with diabetes than in those without diabetes: 37 ± 15 g (95% CI: 33–41) and 47 ± 21 g (95% CI: 40–53), p = 0.017. Patients with acute infarction and diabetes mellitus had higher extracellular volume values in both healthy myocardium: 24% [22–27] and 28% [24–30], p = 0.002, and in the infarct zone: 48% [40–58] and 58% [50–61], p = 0.016.Conclusions. In patients with ST-segment elevation myocardial infarction with diabetes mellitus, the infarct size, the edema area, and the value of the extracellular volume fraction both in the infarct area and in the preserved myocardium were larger than in patients without diabetes, which may underlie the development of myocardial dysfunction and further progression of heart failure.
- 3 August 2023
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 13 (1) , 58-72
Open AccessFeatures of myocardial characteristics of patients with acute ST-segment elevation myocardial infarction with diabetes mellitus as assessed by contrast-enhanced cardiac magnetic resonance imaging
Introduction. The presence of diabetes mellitus in patients with acute infarction significantly worsens short- and long-term prognosis, but the features of the course of the infarction in this category of patients have not been fully studied.Objective. To compare clinical, functional and structural myocardial characteristics of patients with acute ST-segment elevation myocardial infarction with and without diabetes mellitus.Materials and methods. The study included 91 patients with revascularized ST-segment elevation myocardial infarction (41 patients with diabetes mellitus). All patients underwent cardiac MRI with contrast, including myocardial T1 mapping, tissue analysis of left ventricular myocardium with determination of infarct zone, heterogeneous zone, edema zone, pre- and post-contrast T1 values, extracellular volume values of healthy myocardium and infarct zone.Results. The presence of diabetes in patients with AMI was associated with increased EDV LV: 153 ± 38 and 181 ± 58 ml (p = 0.007), increased ESV LV: 76 ml [54–93] and 87 ml [71–122] (p = 0.035). Infarct size was significantly larger in patients with diabetes than in those without diabetes: 37 ± 15 g (95% CI: 33–41) and 47 ± 21 g (95% CI: 40–53), p = 0.017. Patients with acute infarction and diabetes mellitus had higher extracellular volume values in both healthy myocardium: 24% [22–27] and 28% [24–30], p = 0.002, and in the infarct zone: 48% [40–58] and 58% [50–61], p = 0.016.Conclusions. In patients with ST-segment elevation myocardial infarction with diabetes mellitus, the infarct size, the edema area, and the value of the extracellular volume fraction both in the infarct area and in the preserved myocardium were larger than in patients without diabetes, which may underlie the development of myocardial dysfunction and further progression of heart failure.